Последние достижения в лечении метастатического рака предстательной железы

Автор: Солодкий В.А., Павлов А.Ю., Дзидзария А.Г., Мирзаханов Р.И., Гафанов Р.А.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Статья в выпуске: 4 т.21, 2021 года.

Бесплатный доступ

С появлением новых препаратов за последнее десятилетие произошла революция в лечении метастатического рака предстательной железы (РПЖ). В нескольких клинических исследованиях сообщалось об улучшении отдалённых результатов лечения у пациентов с метастатическим кастрационно-резистентным РПЖ (мКРРПЖ) за счет проведения химиотерапии доцетакселом или новых гормональных препаратов (абиратерон, энзалутамид или апалутамид) на фоне продолжающейся андрогенной депривации. Релуголикс былнедавно одобрен в качестве первого перорального антагониста ЛГРГ у пациентов, имеющих серьезные сердечно-сосудистые заболевания в анамнезе. Релуголикс отличается более выраженным подавлением сывороточного тестостерона по сравнению с агонистом ЛГРГ - лейпролидом. Ингибиторы поли-АДФ-рибозы (олапариб и рукапариб), получившие одобрение FDA (Food and Drug Administration), продемонстрировали значительную клиническую эффективность для пациентов с патогенными мутациями в генах гомологичной рекомбинации. Недавно было показано, что лютеций-177-ПСМА-617 при стандартном лечении улучшает общую выживаемость у мужчин с поздней стадией ПСМА- положительного мКРРПЖ. Ожидается, что эти недавние достижения и продолжающиеся исследования множества новых препаратов будут способствовать улучшению результатов выживаемости мужчин с мКРРПЖ в ближайшие годы.

Еще

Метастатический кастрационно-чувствительный рак предстательной железы, метастатический кастрационно-резистентный рак предстательной железы, андроген-депривационная терапия, доцетаксел, абиратерон, энзалутамид, апалутамид

Короткий адрес: https://sciup.org/149139214

IDR: 149139214

Список литературы Последние достижения в лечении метастатического рака предстательной железы

Каприн А.Д., Старинский В.В., А.О. Шахзадова А.О. (ред.). Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). М., 2020. МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России. 252 с.
National Comprehensive Cancer Network: Prostate Cancer (Version 2.2021). Адрес доступа https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (дата доступа 15.12.2021).
Hussain M., Tangen C.M., Berry D.L., et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013. V. 368. No. 14. P. 1314-1325. DOI: 10.1056/NEJMoa1212299
Kyriakopoulos C.E., Chen Y.H., Carducci M.A., et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018. V. 36. No. 11. P. 1080-1087. DOI: 10.1200/JCO.2017.75.3657.
James N.D., Sydes M.R., Clarke N.W., et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016. V. 387. No. 10024. P. 1163-1177. DOI: 10.1016/S0140-6736(15)01037-5.
Gravis G., Boher J.M., Joly F., et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: Impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016. V. 70. No. 2. P. 256-262. DOI: 10.1016/j.eururo.2015.11.005.
Sathianathen N.J., Philippou Y.A., Kuntz G.M., et al. Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2018. V. 10. No. 10. Article ID CD012816. DOI: 10.1002/14651858.CD012816.pub2.
Fizazi K., Tran N., Fein L., et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019. V. 20. No. 5. P. 686-700. DOI: 10.1016/S1470-2045(19)30082-8.
Chi K.N., Protheroe A., Rodriguez-Antolin A., et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): An international, randomised phase 3 trial. Lancet Oncol. 2018. V. 19. No. 2. P. 194-206. DOI: 10.1016/S1470-2045(17)30911-7.
Swami U., McFarland T.R., Nussenzveig R., et al. Advanced prostate cancer: Treatment advances and future directions. Trends Cancer. 2020. V. 6. No. 8. P. 702-715. DOI: 10.1016/j.trecan.2020.04.010
James N.D., de Bono J.S., Spears M.R., et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017. V. 377. No. 4. P. 338-351. DOI: 10.1056/NEJMoa1702900.
Hoyle A.P., Ali A., James N.D., et al. Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer. Eur Urol. 2019. V. 76. No. 6. P. 719-728. DOI: 10.1016/j.eururo.2019.08.006.
Chi K.N., Agarwal N., Bjartell A., et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019. V. 381. No. 1. P. 13-24. DOI: 10.1056/NEJMoa1903307.
Agarwal N., McQuarrie K., Bjartell A., et al. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): A randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2019. V. 20. No. 11. P. 1518-1530. DOI: 10.1016/S1470-2045(19)30620-5.
Chi K.N., Chowdhury S., Bjartell A., et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: Final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021. V. 39. No. 20. P. 2294-2303. DOI: 10.1200/JCO.20.03488.
Davis I.D., Martin A.J., Stockler M.R., et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019. V. 381. No. 2. P. 121-131. DOI: 10.1056/NEJMoa1903835.
Armstrong A.J., Szmulewitz R.Z, Petrylak D.P., et al. ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019. V. 37. No. 32. P. 2974-2986. DOI: 10.1200/JCO.19.00799.
Shore N.D., Saad F., Cookson M.S., et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020. V. 382. No. 23. P. 2187-2196. DOI: 10.1056/NEJMoa2004325.
Berthold D.R., Pond G.R., Soban F., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol. 2008. V. 26. No. 2. P. 242-245. DOI: 10.1200/JCO.2007.12.4008.
de Bono J.S., Oudard S., Ozguroglu M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet. 2010. V. 376. No. 9747. P. 1147-1154. DOI: 10.1016/S0140-6736(10)61389-X.
Eisenberger M., Hardy-Bessard A.C., Kim C.S., et al. Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol. 2017. V. 35. No. 28. P. 3198-3206. DOI: 10.1200/JCO.2016.72.1076.
Oudard S., Fizazi K., Sengelov L., et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: A randomized phase III trial-FIRSTANA. J Clin Oncol. 2017. V. 35. No. 28. P. 3189-3197. DOI: 10.1200/JCO.2016.72.1068.
de Bono J.S., Logothetis C.J., Molina A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011. V. 364. No. 21. P. 1995-2005. DOI: 10.1056/NEJMoa1014618.
Ryan C.J., Smith M.R., Fizazi K., et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015. V. 16. No. 2. P. 152-160. DOI: 10.1016/S1470-2045(14)71205-7.
Scher H.I., Fizazi K., Saad F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012. V. 367. No. 13. P. 1187-1197. DOI: 10.1056/NEJMoa1207506.
Beer T.M., Armstrong A.J., Rathkopf D.E., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014. V. 371. No. 5. P. 424-433. DOI: 10.1056/NEJMoa1405095
Parker C., Nilsson S., Heinrich D., et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013. V. 369. No. 3. P. 213-223. DOI: 10.1056/NEJMoa1213755.
Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010. V. 363. No. 5. P. 411-422. DOI: 10.1056/NEJMoa1001294.
Abida W., Cheng M.L., Armenia J., et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 2019. V. 5. No. 4. P. 471-478. DOI: 10.1001/jamaoncol.2018.5801.
US Food and Drug Administration. Pembrolizumab Prescribing Information. 2021. Адрес доступа https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s096lbl.pdf (дата доступа 15.12.2021).
Morris M.J., De Bono J.S., Chi K.N., et al. Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). J Clin Oncol. 2021. V. 39. Suppl 15. Abstr. LBA4. DOI: DOI: 10.1200/JCO.2021.39.15_suppl.LBA4.
de Bono J., Mateo J., Fizazi K., et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020. V. 382. No. 22. P. 2091-2102. DOI: 10.1056/NEJMoa1911440.
Hussain M., Mateo J., Fizazi K., et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020. V. 383. No. 24. P. 2345-2357. DOI: 10.1056/NEJMoa2022485.
US Food and Drug Administration. Hematology/Oncology (Cancer) Approvals & Safety Notifications. 2020. Адрес доступа https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications (дата доступа 15.12.2021).
Abida W., Patnaik A., Campbell D., et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol. 2020. V. 38. No. 32. P. 3763-3772. DOI: 10.1200/JCO.20.01035.
Abida W., Campbell D., Patnaik A., et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: Analysis from the phase II TRITON2 study. Clin Cancer Res. 2020. V. 26. No. 11. P. 2487-2496. DOI: 10.1158/1078-0432.CCR-20-0394.
De Bono J.S., Mehra N., Higano C.S., et al. TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA). J Clin Oncol. 2020. V. 38. No. 6 suppl. P. 119. DOI: 10.1200/JCO.2020.38.6_suppl.119.
Smith M.R., Sandhu S.K., Kelly W.K., et al. Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD). Ann Oncol. 2019. V. 30. Suppl. 5. P. v884-v885. DOI: 10.1093/annonc/mdz394.043.
Sathianathen N.J., Koschel S., Thangasamy I.A., et al. Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis. Eur Urol. 2020. V. 77. No. 3. P. 365-372. DOI: 10.1016/j.eururo.2019.09.004.
Sydes M.R., Spears M.R., Mason M.D., et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: Directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018. V. 29. No. 5. P. 1235-1248. DOI: 10.1093/annonc/mdy072.
Rush H.L., Cook A.D., Brawley C.D., et al. Comparative quality of life in patients randomized contemporaneously to docetaxel or abiraterone in the STAMPEDE trial. J Clin Oncol. 2020. V. 38. No. 6 (suppl.). P. 14. DOI: 10.1200/JCO.2020.38.6_suppl.14.
Fizazi K., Tran N., Fein L., et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017. V. 377. No. 4. P. 352-360. DOI: 10.1056/NEJMoa1704174.
Morris M.J., Rumble R.B., Basch E., et al. Optimizing anticancer therapy in metastatic non-castrate prostate cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018. V. 36. No. 15. P. 1521-1539. DOI: 10.1200/JCO.2018.78.0619.
Khalaf D.J., Annala M., Taavitsainen S., et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: A multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 2019. V. 20. No. 12. P. 1730-1739. DOI: 10.1016/S1470-2045(19)30688-6.
de Wit R., de Bono J., Sternberg C.N., et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019. V. 381. No. 26. P. 2506-2518. DOI: 10.1056/NEJMoa1911206.
Freedland S.J., Sandin R., Sah J., et al. Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study. J Clin Oncol. 2021. V. 39. No. 6 (suppl.). P. 46. DOI: 10.1200/JCO.2021.39.6_suppl.46.
Maluf F.C., Pereira F.M.T., Serrano Uson P.L. Jr., et al. Consensus for treatment of metastatic castration-sensitive prostate cancer: Report from the first global prostate cancer consensus conference for developing countries (PCCCDC). JCO Glob Oncol. 2021. V. 7. No. 7. P. 550-558. DOI: 10.1200/GO.20.00505.
Szmulewitz R.Z., Peer C.J., Ibraheem A., et al. Prospective international randomized phase II study of low-dose abiraterone with Food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol. 2018. V. 36. No. 14. P. 1389-1395. DOI: 10.1200/JCO.2017.76.4381.
de Bono J.S., Bracarda S., Sternberg C.N., et al. LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol. 2020. V. 31 P. S1153-S1154. DOI: 10.1016/j.annonc.2020.08.2250.
Agarwal N., Loriot Y., McGregor B.A., et al. Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of Cohort 6 of the COSMIC-021 Study. J Clin Oncol. 2020. V. 38. No. 6 (suppl.). P. 5564. DOI: 10.1200/JCO.2020.38.6_suppl.139.
Petrylak D.P., Gao X., Vogelzang N.J., et al. First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI). J Clin Oncol. 2020. V. 38. No. 15 (suppl.). P. 3500. DOI: 10.1200/JCO.2020.38.15_suppl.3500.
Rathi N., McFarland T.R., Nussenzveig R., et al. Evolving role of immunotherapy in metastatic castration refractory prostate cancer. Drugs. 2021. V. 81. No. 2. P. 191-206. DOI: 10.1007/s40265-020-01456-z.

Еще

Статья научная